Tehran University of Medical Sciences

Science Communicator Platform

Share By
Vaccines for Preventing Cutaneous Leishmaniasis Publisher



Khanjani N1 ; Gonzalez U2 ; Leonardibee J3 ; Mohebali M4 ; Saffari M5 ; Khamesipour A6
Authors

Source: Cochrane Database of Systematic Reviews Published:2018


Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate if vaccination with each of the different available vaccines reduces the occurrence of cutaneous leishmaniasis (CL) in endemic regions © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Related Docs
View other Related Docs
1. Improving Adverse Drug Event Reporting by Health Care Professionals, Cochrane Database of Systematic Reviews (2017)
2. Fluoxetine for Multiple Sclerosis, Cochrane Database of Systematic Reviews (2018)
3. Mobile Phone Text Messaging for the Prevention of Sexually Transmitted Infections, Cochrane Database of Systematic Reviews (2019)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (3)
Arash Rashidian (1)
Other Related Docs
4. Healthcare Workers’ Informal Uses of Mobile Devices to Support Their Work: A Qualitative Evidence Synthesis, Cochrane Database of Systematic Reviews (2023)
5. Stem Cell Therapy for Multiple Sclerosis, Cochrane Database of Systematic Reviews (2019)
6. An Overview of Leishmanization Experience: A Successful Control Measure and a Tool to Evaluate Candidate Vaccines, Acta Tropica (2019)
7. Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (Alm) and Quillaja Saponins, Iranian Journal of Pharmaceutical Research (2016)
8. Cationic Liposomes Formulated With a Novel Whole Leishmania Lysate (Wll) As a Vaccine for Leishmaniasis in Murine Model, Immunobiology (2018)
9. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania Major (Alum-Alm) Vaccine Mixed With Bcg Plus Imiquimod Vs. Placebo Control Group, Iranian Journal of Parasitology (2015)
10. Potential Biomarkers of Immune Protection in Human Leishmaniasis, Medical Microbiology and Immunology (2021)
11. Immunization Against Leishmania Major Infection in Balb/C Mice Using a Subunit-Based Dna Vaccine Derived From Tsa, Lmsti1, Kmp11, and Lack Predominant Antigens, Iranian Journal of Basic Medical Sciences (2019)
12. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
13. Evaluation of Immune Response Against Leishmaniasis in Balb/C Mice Immunized With Cationic Dotap/Dope/Chol Liposomes Containing Soluble Leishmania Major Antigens, Iranian Journal of Parasitology (2019)
14. Pegylation of Cationic Liposomes Encapsulating Soluble Leishmania Antigens Reduces the Adjuvant Efficacy of Liposomes in Murine Model, Parasite Immunology (2017)
15. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation, Iranian Journal of Immunology (2015)
16. The Role of Iscomatrix Bilayer Composition to Induce a Cell Mediated Immunity and Protection Against Leishmaniasis in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2016)
17. An Alphavirus-Derived Self-Amplifying Mrna Encoding Ppsp15-Lmsti1 Fusion Protein for the Design of a Vaccine Against Leishmaniasis, Parasitology International (2022)
18. Engineering and Design of Promising T-Cell-Based Multi-Epitope Vaccine Candidates Against Leishmaniasis, Scientific Reports (2023)
19. Comparison of Cytokine Profile of Ifn-Γ, Il-5 and Il-10 in Cutaneous Leishmaniasis Using Pbmc Vs. Whole Blood, Iranian Journal of Microbiology (2019)
20. The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model, Immunopharmacology and Immunotoxicology (2018)